 SILVER SPRING, Md., Oct. 25, 2021 GLOBE NEWSWIRE -- Aziyo Biologics, Inc. Nasdaq: AZYO, a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it was informed by Medtronic that, after conducting a thorough review of customer and patient needs, Medtronic has made the decision to cease distribution of Cellular Bone Matrix CBM products. As a result of this decision, the two companies are working toward a mutual termination of their FiberCel distribution agreement. 